高级搜索
立即登录 | 免费注册
当前位置 >   首页 > 期刊文献 > 全球精选文摘 > 文摘导读
司来吉兰经皮给药治疗HIV相关性认知功能障碍的多中心研究
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
Schifitto G, for the ACTG A5090 Team  2009/5/27 10:50:12 
【发表评论】 【全球专家评论】
打印| 推荐给好友
Neurology, 2007,
专家评级：
★★
 		循证评级：
A
      View at Publisher
Abstract

Background:

Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance.

Methods:

HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3mg/24 hours, STS 6mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests.

Results:

A total of 128 subjects (88% men, 51% white) were enrolled, median age 45 years. Most subjects (62%) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (−0.28, 0.55) for the selegiline 3mg/24 hours arm, 0.21 (−0.18, 0.62) for the selegiline 6mg/24hours arm, and 0.28 (−0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p=0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms.

Conclusion:

Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.
  评论

请登录后发表评论，点击此处登录。

疾病资源中心  疾病资源中心
病例分析 <span class="ModTitle_Intro_Right" id="EPMI_Home_MedicalCases_Intro_div" onclick="javascript:window.location='http://portal.elseviermed.cn/tabid/127/Default.aspx'" onmouseover="javascript:document.getElementById('EPMI_Home_MedicalCases_Intro_div').style.cursor='pointer';document.getElementById('EPMI_Home_MedicalCases_Intro_div').style.textDecoration='underline';" onmouseout="javascript:document.getElementById('EPMI_Home_MedicalCases_Intro_div').style.textDecoration='none';">[栏目介绍]</span>  病例分析 [栏目介绍]
呼吸急促伴精神状态改变——《西氏内科学》病例

摘自：《西氏内科学》，第23版

 

患者男性，36岁，幼年有吸入性肺损伤史，因呼吸急促和精神状态改变来我院就诊。患者睡眠和运动时，吸氧流量基值为2 L/min，每天均进行肺功能康复训练。患者居住在美国中西部，入院5天前曾离家乘船来这里看望其兄弟。入院前一天，患者呼吸急促加剧，自觉发热并注意到其慢性咳嗽稍加重，但痰液无变化。当天晚上，家人注意到患者更加急躁并有点偏执。由于症状加重，患者于次日送我院就诊。

更多>>>
医学数据库  医学数据库